4387 Dihydrouracil Dihydrouracil is an intermediate breakdown product of uracil. Dihydropyrimidine dehydrogenase catalyzes the reduction of uracil to 5, 6-dihydrouracil then dihydropyrimidinase hydrolyzes 5, 6-dihydrouracil to N-carbamyl-b-alanine. Finally, beta-ureidopropionase catalyzes the conversion of N-carbamyl-b-alanine to beta-alanine. Patients with dihydropyrimidinase deficiency (DPYS; also called 5, 6-dihydropyrimidine amidohydrolase, or DHP; EC 3.5.2.2) exhibit highly increased concentrations of 5, 6-dihydrouracil in urine. The direct measurement of the activity of DHP in patients had been hampered by the fact that the enzyme is expressed almost exclusively in liver tissue. Various neurological abnormalities have been described in this group of patients. (OMIM 222748). 504-07-4 649 C4H6N2O2 White powder. 279 - 281°C No indication of carcinogenicity to humans (not listed by IARC). This is an endogenously produced metabolite found in the human body. It is used in metabolic reactions, catabolic reactions or waste generation. 2014-08-29T06:28:48Z 2026-05-14T17:18:14Z C00429 15901 DI-H-URACIL DB01849 DUC true O=C1CCNC(=O)N1 C4H6N2O2 InChI=1S/C4H6N2O2/c7-3-1-2-5-4(8)6-3/h1-2H2,(H2,5,6,7,8) OIVLITBTBDPEFK-UHFFFAOYSA-N 114.1026 114.042927446 Endogenous Solid -1.2 HMDB00076 629 CHEM003293 DTXSID7060122 1,3-diazinane-2,4-dione 58.2 25.745500000000003 10.133629968746801 0 2 2 11.726846896036472 -7.628772459765097 0 1 -1.28 -0.64 2.59e+01 g/l